ADMA Biologics Inc. [NASDAQ: ADMA] gained 4.89% on the last trading session, reaching $3.86 price per share at the time. The company report on December 13, 2022 that ADMA Biologics Announces FDA Approval for Room Temperature Storage of ASCENIV™ & BIVIGAM®.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
FDA approvals for both ASCENIV and BIVIGAM provide for room temperature (25°C) storage conditions for up to 4 weeks during the first 24 months of the 36-month approved shelf life.
Provides for improved inventory management and ease of product administration to patients.
ADMA Biologics Inc. represents 196.38 million in outstanding shares, while the company has a total market value of $875.10 million with the latest information. ADMA stock price has been found in the range of $3.67 to $3.92.
If compared to the average trading volume of 3.25M shares, ADMA reached a trading volume of 3092360 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about ADMA Biologics Inc. [ADMA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ADMA shares is $5.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ADMA stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Mizuho have made an estimate for ADMA Biologics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 13, 2022. The new note on the price target was released on November 11, 2021, representing the official price target for ADMA Biologics Inc. stock. Previously, the target price had yet another raise to $4.50, while Cantor Fitzgerald analysts kept a Overweight rating on ADMA stock.
The Average True Range (ATR) for ADMA Biologics Inc. is set at 0.17, with the Price to Sales ratio for ADMA stock in the period of the last 12 months amounting to 6.71. The Price to Book ratio for the last quarter was 7.57, with the Price to Cash per share for the same quarter was set at 0.15.
Trading performance analysis for ADMA stock
ADMA Biologics Inc. [ADMA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 4.61. With this latest performance, ADMA shares gained by 16.27% in over the last four-week period, additionally plugging by 94.95% over the last 6 months – not to mention a rise of 196.92% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ADMA stock in for the last two-week period is set at 64.78, with the RSI for the last a single of trading hit 66.53, and the three-weeks RSI is set at 63.67 for ADMA Biologics Inc. [ADMA]. The present Moving Average for the last 50 days of trading for this stock 3.18, while it was recorded at 3.72 for the last single week of trading, and 2.43 for the last 200 days.
ADMA Biologics Inc. [ADMA]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and ADMA Biologics Inc. [ADMA] shares currently have an operating margin of -72.41 and a Gross Margin at +0.57. ADMA Biologics Inc.’s Net Margin is presently recorded at -88.52.
Return on Equity for this stock declined to -62.46, with Return on Assets sitting at -29.61.
ADMA Biologics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.40 and a Current Ratio set at 5.00.
An analysis of insider ownership at ADMA Biologics Inc. [ADMA]
There are presently around $501 million, or 67.30% of ADMA stock, in the hands of institutional investors. The top three institutional holders of ADMA stocks are: BLACKROCK INC. with ownership of 12,975,594, which is approximately 3.057% of the company’s market cap and around 1.50% of the total institutional ownership; PERCEPTIVE ADVISORS LLC, holding 10,933,387 shares of the stock with an approximate value of $42.2 million in ADMA stocks shares; and STATE STREET CORP, currently with $36.37 million in ADMA stock with ownership of nearly 217.905% of the company’s market capitalization.
Positions in ADMA Biologics Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 72 institutional holders increased their position in ADMA Biologics Inc. [NASDAQ:ADMA] by around 26,976,497 shares. Additionally, 48 investors decreased positions by around 16,619,703 shares, while 25 investors held positions by with 86,188,797 shares. The mentioned changes placed institutional holdings at 129,784,997 shares, according to the latest SEC report filing. ADMA stock had 29 new institutional investments in for a total of 5,693,158 shares, while 15 institutional investors sold positions of 1,483,789 shares during the same period.